A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer

European Journal of Cancer and Clinical Oncology

Volumn 26, Issue 3, 1990, Pages 337-343

  Willemse, Pax H B ^a   Van Der Ploeg, Els ^a   Sleijfer, Dirk T H ^a   Tjabbes, Ton ^a   Van Veelen, Henk ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; COMPARATIVE STUDY; FEMALE; HEARTBURN; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VERTIGO;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPARATIVE STUDY; FEMALE; HUMAN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL; MEGESTROL ACETATE; MIDDLE AGE; RANDOMIZED CONTROLLED TRIALS;

EID: 0025303837     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(90)90231-H     Document Type: Article

References (23)

1. Oral versus i.m. administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer
2. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer
3. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer
4. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high dose medroxyprogesterone acetate
5. Megestrolazetat in verschiedenen Dosierungen bei der Behandlung des metastasierenden Mammakarzinoms—klinische und endokrinologische Untersuchungen
6. Oral high-dose medroxyprogesterone acetate versus tamoxifen
7. Clinical trial of high-dose medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature
8. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer
9. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities
10. Megestrol acetate in the treatment of advanced post-menopausal breast cancer
11. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment
12. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate: dose relations, metabolic and endocrine effects
13. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients
14. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer
15. Adrenal suppression as parameter of the bioavailability of MA and MPA in patients with advanced breast cancer
16. Factors predicting the response of patients with advanced breast cancer to endocrine (megace) therapy
17. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time
18. Megestrol acetate therapy for advanced breast cancer
19. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients
20. High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer
21. Appetite stimulation with megestrol acetate in cachectic cancer patients
22. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer
23. Cardiovascular side-effects under medroxyprogesterone acetate treatment